Literature DB >> 9484407

Interferon treatment for multiple sclerosis: autoimmune complications may be lethal.

L Durelli1, M R Bongioanni, B Ferrero, A Oggero, A Marzano, M Rizzetto.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9484407     DOI： 10.1212/wnl.50.2.570

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  9 in total

1.  Hydration and protein folding in water and in reverse micelles: compressibility and volume changes.

Authors:  D Valdez; J Y Le Huérou; M Gindre; W Urbach; M Waks
Journal:  Biophys J       Date:  2001-06       Impact factor: 4.033

2.  Development of autoimmune hepatitis type 1 after pulsed methylprednisolone therapy for multiple sclerosis: a case report.

Authors:  Atsushi Takahashi; Yukiko Kanno; Yuta Takahashi; Natsumi Sakamoto; Kyoko Monoe; Hironobu Saito; Kazumichi Abe; Junko Yokokawa; Atsushi Irisawa; Hiromasa Ohira
Journal:  World J Gastroenterol       Date:  2008-09-21       Impact factor: 5.742

Review 3.  Hepatic injury, liver monitoring and the beta-interferons for multiple sclerosis.

Authors:  Helen Tremlett; Joel Oger
Journal:  J Neurol       Date:  2004-11       Impact factor: 4.849

Review 4.  Managing the adverse effects of interferon-beta therapy in multiple sclerosis.

Authors:  A Bayas; P Rieckmann
Journal:  Drug Saf       Date:  2000-02       Impact factor: 5.606

Review 5.  US FDA-approved disease-modifying treatments for multiple sclerosis: review of adverse effect profiles.

Authors:  Steven L Galetta; Clyde Markowitz
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

6.  Hepatic reactions during treatment of multiple sclerosis with interferon-beta-1a: incidence and clinical significance.

Authors:  Gordon S Francis; Yves Grumser; Enrica Alteri; Alain Micaleff; Fanny O'Brien; Jonathan Alsop; Margaretha Stam Moraga; Neil Kaplowitz
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

7.  Concurrent autoimmune hepatitis and grave's disease in hepatitis C during pegylated interferon α-2a and ribavirin therapy.

Authors:  Guru V Trikudanathan; Imad Ahmad; Jonathan L Israel
Journal:  Saudi J Gastroenterol       Date:  2011 Sep-Oct       Impact factor: 2.485

8.  Presentation and outcomes with clinically apparent interferon beta hepatotoxicity.

Authors:  Robert J Fontana; Paul Hayashi; Herbert L Bonkovsky; David E Kleiner; Sweta Kochhar; Jiezhun Gu; Marwan Ghabril
Journal:  Dig Dis Sci       Date:  2013-02-02       Impact factor: 3.487

Review 9.  The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review.

Authors:  Marco Biolato; Assunta Bianco; Matteo Lucchini; Antonio Gasbarrini; Massimiliano Mirabella; Antonio Grieco
Journal:  CNS Drugs       Date:  2021-07-28       Impact factor: 5.749
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.